Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data. - Wikidata - thesis-toulmin - TriplyDB

Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data.

Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data.

http://www.wikidata.org/entity/Q30612998

about

Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospe

P2860

Q50703895-5E8525C1-5965-4EC4-AF26-9DF582D60F8E

P2860

Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data.

http://www.wikidata.org/entity/Q30612998

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Remission in patients with act ...... prospectively registered data.

@ast

Remission in patients with act ...... prospectively registered data.

@en

type

label

Remission in patients with act ...... prospectively registered data.

@ast

Remission in patients with act ...... prospectively registered data.

@en

prefLabel

Remission in patients with act ...... prospectively registered data.

@ast

Remission in patients with act ...... prospectively registered data.

@en

P1433

Q30612998-6823EBF7-44BA-4CD1-B1D6-B4B7113B68FA

P1476

Q30612998-63DF2159-703C-437F-9061-949E99688810

P2093

Q30612998-045D2E7B-BC5A-43B7-92EC-7B479A694B19

Q30612998-103784BC-E84C-41D9-9601-607AB8099206

Q30612998-1356C575-B41A-475C-A276-19C04C5E819E

Q30612998-243CDFAC-4BB6-47DF-88C8-000205743EAF

Q30612998-25EBBEA9-A8DD-4D36-B459-43C8860C0F46

Q30612998-32F715B4-D38A-4C30-80D7-FA3D10056C42

Q30612998-34AB0A30-3AE3-4D46-A413-2F3DB84B8ED7

Q30612998-4F9D3698-A355-4D32-816E-E18514C9507A

Q30612998-5DC7682C-DF82-40B0-A751-2B4BE8499184

Q30612998-74B75806-93B8-4048-BE18-A3A9CFC89979

P2860

Q30612998-056F44E0-7AE0-47E8-B369-3CF12B7C6E56

Q30612998-151B2476-DD9B-4E96-9A8B-5A35B38A1D4B

Q30612998-22910330-3432-4511-BFE5-7DBEC03C54C1

Q30612998-40460565-1FCB-4F62-8708-E830144050E8

Q30612998-4EC5D7EC-F8E9-4995-BAB3-58DADF576335

Q30612998-59B67080-ED1C-469E-9D77-E51F89CF1678

Q30612998-59E30925-2C79-44F5-A513-DF203F7B285F

Q30612998-9FC611B9-A609-4043-B10A-AC4AB833A184

Q30612998-B9B4CADC-08E0-4338-9F88-7751DBA2CD73

Q30612998-C0034669-8625-42B5-9CED-28F4A1C24F84

P2888

Q30612998-BDAAACD0-8CF9-48B9-9883-11D6AE7443E5

P31

Q30612998-07D380CC-06E6-486D-B74A-18110E0CC480

P356

Q30612998-D481FE5B-B497-4AF9-A692-5790DF098831

P577

Q30612998-544FAD4A-C2DA-466D-9740-6B1873C2FF7D

P6179

Q30612998-7F8DCC3D-A175-4AC4-922E-C8BB39B8E0ED

P698

Q30612998-F232932E-A56B-4E07-9385-07AAD594551E

P356

S10165-013-0878-Z

P1433

Modern Rheumatology

P1476

Remission in patients with act ...... prospectively registered data.

@en

P2093

Eiichi Suematsu

http://www.w3.org/2001/XMLSchema#string

Eisuke Shono

http://www.w3.org/2001/XMLSchema#string

Hiroaki Nishizaka

http://www.w3.org/2001/XMLSchema#string

Hiroshi Harada

http://www.w3.org/2001/XMLSchema#string

Hiroshi Jojima

http://www.w3.org/2001/XMLSchema#string

Hisaaki Miyahara

http://www.w3.org/2001/XMLSchema#string

Hitoshi Nakashima

http://www.w3.org/2001/XMLSchema#string

Ken Wada

http://www.w3.org/2001/XMLSchema#string

Koji Kuroda

http://www.w3.org/2001/XMLSchema#string

Masakazu Kondo

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic dr

Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials.

Treating rheumatoid arthritis to target: recommendations of an international task force.

Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study.

Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria.

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

P2888

s10165-013-0878-z

P31

scholarly article

P356

10.1007/S10165-013-0878-Z

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1045302288

http://www.w3.org/2001/XMLSchema#string

P698

23563508

http://www.w3.org/2001/XMLSchema#string